Aspirin-Intolerant Asthma: A Comprehensive Review of Biomarkers and Pathophysiology
详细信息 查看全文
- 作者：Juan R. Velazquez (1)
Luis M. Teran (1) - 关键词：Asthma ; Aspirin ; Biomarker
- 刊名：Clinical Reviews in Allergy & Immunology
- 出版年：2013
- 出版时间：August 2013
- 年：2013
- 卷：45
- 期：1
- 页码：75-86
- 全文大小：279KB
- 参考文献：1. Pfaar O, Klimek L (2006) Eicosanoids, aspirin-intolerance and the upper airways鈥攃urrent standards and recent improvements of the desensitization therapy. J Physiol Pharmacol 57(Suppl 12):5鈥?3
2. Samter M, Beers RF Jr (1968) Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68:975鈥?83 CrossRef
3. Lee RU, Stevenson DD (2011) Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 3:3鈥?0 CrossRef
4. Laitinen LA, Laitinen A, Haahtela T (1993) Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 147:697鈥?04 CrossRef
5. Szczeklik A (1992) Aspirin-induced asthma: pathogenesis and clinical presentation. Allergy Proc 13:163鈥?73 CrossRef
6. Babu KS, Salvi SS (2000) Aspirin and asthma. Chest 118:1470鈥?476 CrossRef
7. Szczeklik A, Stevenson DD (2003) Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111:913鈥?21 CrossRef
8. Kim SH, Hur GY, Choi JH, Park HS (2008) Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 9:85鈥?1 CrossRef
9. Palikhe NS, Kim SH, Park HS (2008) What do we know about the genetics of aspirin intolerance? J Clin Pharm Ther 33:465鈥?72 CrossRef
10. Balsinde J, Winstead MV, Dennis EA (2002) Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 531:2鈥? CrossRef
11. Schievella AR, Regier MK, Smith WL, Lin LL (1995) Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 270:30749鈥?0754 CrossRef
12. van der Donk WA, Tsai AL, Kulmacz RJ (2002) The cyclooxygenase reaction mechanism. Biochemistry 41:15451鈥?5458 CrossRef
13. Smith HS (2006) Arachidonic acid pathways in nociception. J Support Oncol 4:277鈥?87
14. Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205鈥?29
15. Kennedy I, Coleman RA, Humphrey PP, Levy GP, Lumley P (1982) Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins 24:667鈥?89
16. Narumiya S, FitzGerald GA (2001) Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108:25鈥?0
17. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255鈥?61 CrossRef
18. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS (2001) Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98:1942鈥?948 CrossRef
19. Vancheri C, Mastruzzo C, Sortino MA, Crimi N (2004) The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 25:40鈥?6 CrossRef
20. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB (2003) Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29:537鈥?44 CrossRef
21. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164:1663鈥?667
22. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, Kornatowski T, Kaliner MA (2000) Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 161:391鈥?98 CrossRef
23. Swierczynska M, Nizankowska-Mogilnicka E, Zarychta J, Gielicz A, Szczeklik A (2003) Nasal versus bronchial and nasal response to oral aspirin challenge: clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. J Allergy Clin Immunol 112:995鈥?001 CrossRef
24. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A (2008) Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 63:27鈥?4 CrossRef
25. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL (1988) Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 137:847鈥?54 CrossRef
26. Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V, Montserrat JM, Gelpi E (1992) Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 145:65鈥?9 CrossRef
27. Sanak M, Kielbasa B, Bochenek G, Szczeklik A (2004) Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy 34:1899鈥?904 CrossRef
28. Sladek K, Dworski R, Soja J, Sheller JR, Nizankowska E, Oates JA, Szczeklik A (1994) Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 149:940鈥?46 CrossRef
29. Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A (2011) Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 127:1141鈥?147 CrossRef
30. Peters-Golden M, Henderson WR Jr (2007) Leukotrienes. N Engl J Med 357:1841鈥?854 CrossRef
31. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH (2006) Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 117:312鈥?18 CrossRef
32. Sousa A, Pfister R, Christie PE, Lane SJ, Nasser SM, Schmitz-Schumann M, Lee TH (1997) Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 52:940鈥?45 CrossRef
33. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam BK, Penrose JF, Austen FK, Holgate ST, Sampson AP (1998) Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101:834鈥?46 CrossRef
34. Adamjee J, Suh YJ, Park HS, Choi JH, Penrose JF, Lam BK, Austen KF, Cazaly AM, Wilson SJ, Sampson AP (2006) Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 209:392鈥?99 CrossRef
35. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, Mullol J (1999) Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 160:291鈥?96 CrossRef
36. Gronert K, Clish CB, Romano M, Serhan CN (1999) Transcellular regulation of eicosanoid biosynthesis. Methods Mol Biol 120:119鈥?44
37. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B (1980) Leukotrienes are potent constrictors of human bronchi. Nature 288:484鈥?86 CrossRef
38. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH (1991) Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 143:1025鈥?029 CrossRef
39. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, Oates J (1996) Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 154:1608鈥?614 CrossRef
40. Corrigan C, Mallett K, Ying S, Roberts D, Parikh A, Scadding G, Lee T (2005) Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 115:316鈥?22 CrossRef
41. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH (2002) Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347:1493鈥?499 CrossRef
42. Cai Y, Bjermer L, Halstensen TS (2003) Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am J Respir Cell Mol Biol 29:683鈥?93 CrossRef
43. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C (2005) Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 115:1189鈥?196 CrossRef
44. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A (2000) Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 23:290鈥?96 CrossRef
45. Gaber F, Daham K, Higashi A, Higashi N, Gulich A, Delin I, James A, Skedinger M, Gyllfors P, Nord M, Dahlen SE, Kumlin M, Dahlen B (2008) Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 63:1076鈥?082 CrossRef
46. Ono E, Taniguchi M, Higashi N, Mita H, Yamaguchi H, Tatsuno S, Fukutomi Y, Tanimoto H, Sekiya K, Oshikata C, Tsuburai T, Tsurikisawa N, Otomo M, Maeda Y, Hasegawa M, Miyazaki E, Kumamoto T, Akiyama K (2011) Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma. Allergol Int 60:37鈥?3 CrossRef
47. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M, Lee TH (1992) Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis 146:1531鈥?534 CrossRef
48. Mastalerz L, Sanak M, Szczeklik A (2001) Serum interleukin-5 in aspirin-induced asthma. Clin Exp Allergy 31:1036鈥?040 CrossRef
49. Hills JM, Sellers AJ, Mistry J, Broekman M, Howson W (1991) Phosphinic acid analogues of GABA are antagonists at the GABAB receptor in the rat anococcygeus. Br J Pharmacol 102:5鈥? CrossRef
50. Farooque SP, Lee TH (2009) Aspirin-sensitive respiratory disease. Annu Rev Physiol 71:465鈥?87 CrossRef
51. Romano M (2010) Lipoxin and aspirin-triggered lipoxins. Sci World J 10:1048鈥?064 CrossRef
52. Ryan A, Godson C (2010) Lipoxins: regulators of resolution. Curr Opin Pharmacol 10:166鈥?72 CrossRef
53. Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101鈥?37 CrossRef
54. Stables MJ, Gilroy DW (2011) Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res 50:35鈥?1 CrossRef
55. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan CN, Szczeklik A (2000) Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 16:44鈥?9 CrossRef
56. Celik GE, Erkekol FO, Misirligil Z, Melli M (2007) Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin Exp Allergy 37:1494鈥?501
57. Serhan CN (2008) Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids 79:157鈥?63 CrossRef
58. Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M (2008) Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 367:509鈥?15 CrossRef
59. Aoki H, Hisada T, Ishizuka T, Utsugi M, Ono A, Koga Y, Sunaga N, Nakakura T, Okajima F, Dobashi K, Mori M (2010) Protective effect of resolvin E1 on the development of asthmatic airway inflammation. Biochem Biophys Res Commun 400:128鈥?33 CrossRef
60. Bilal S, Haworth O, Wu L, Weylandt KH, Levy BD, Kang JX (2011) Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochim Biophys Acta 1812:1164鈥?169 CrossRef
61. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD (2008) Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 9:873鈥?79 CrossRef
62. Lloyd CM, Hessel EM (2010) Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol 10:838鈥?48 CrossRef
63. Velazquez JR, Teran LM (2011) Chemokines and their receptors in the allergic airway inflammatory process. Clin Rev Allergy Immunol 41:76鈥?8 CrossRef
64. Dahlen B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, Zetterstrom O, Dahlen SE (1993) The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 6:1018鈥?026
65. Nasser S, Christie PE, Pfister R, Sousa AR, Walls A, Schmitz-Schumann M, Lee TH (1996) Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 51:64鈥?0 CrossRef
66. Zhang MQ, Timmerman H (1997) Mast cell tryptase and asthma. Mediators Inflamm 6:311鈥?17 CrossRef
67. Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R (2010) The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 126:738鈥?44 CrossRef
68. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, White MV, Igarashi Y, Kaliner MA, Drazen JM (1994) Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 94:1046鈥?056 CrossRef
69. Bosso JV, Schwartz LB, Stevenson DD (1991) Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol 88:830鈥?37 CrossRef
70. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A (2003) A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 111:743鈥?49 CrossRef
71. Celik GE, Schroeder JT, Hamilton RG, Saini SS, Adkinson NF (2009) Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy 39:1522鈥?531 CrossRef
72. Nasser SM, Pfister R, Christie PE, Sousa AR, Barker J, Schmitz-Schumann M, Lee TH (1996) Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 153:90鈥?6 CrossRef
73. Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH (1997) Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 156:1384鈥?389 CrossRef
74. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160:1001鈥?008 CrossRef
75. Wenzel SE (2009) Eosinophils in asthma鈥攃losing the loop or opening the door? N Engl J Med 360:1026鈥?028 CrossRef
76. Varga EM, Jacobson MR, Masuyama K, Rak S, Till SJ, Darby Y, Hamid Q, Lund V, Scadding GK, Durham SR (1999) Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 14:610鈥?15 CrossRef
77. Kupczyk M, Kurmanowska Z, Kuprys-Lipinska I, Bochenska-Marciniak M, Kuna P (2010) Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir Med 104:1404鈥?409 CrossRef
78. Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N (2010) Rhinosinusitis and asthma: a link for asthma severity. Curr Allergy Asthma Rep 10:194鈥?01 CrossRef
79. Perez Novo CA, Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Claeys C, Holtappels G, Van Cauwenberge P, Kowalski ML, Bachert C (2010) T cell inflammatory response, Foxp3 and TNFRS18-L regulation of peripheral blood mononuclear cells from patients with nasal polyps-asthma after staphylococcal superantigen stimulation. Clin Exp Allergy 40:1323鈥?332 CrossRef
80. Hayden MS, Ghosh S (2011) NF-kappaB in immunobiology. Cell Res 21:223鈥?44 CrossRef
81. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956鈥?59 CrossRef
82. Picado C, Bioque G, Roca-Ferrer J, Pujols L, Mullol J, Benitez P, Bulbena O (2003) Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy 58:122鈥?26 CrossRef
83. Mortaz E, Redegeld FA, Nijkamp FP, Engels F (2005) Dual effects of acetylsalicylic acid on mast cell degranulation, expression of cyclooxygenase-2 and release of pro-inflammatory cytokines. Biochem Pharmacol 69:1049鈥?057 CrossRef
84. Aeberhard EE, Henderson SA, Arabolos NS, Griscavage JM, Castro FE, Barrett CT, Ignarro LJ (1995) Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun 208:1053鈥?059 CrossRef
85. Cianferoni A, Schroeder JT, Kim J, Schmidt JW, Lichtenstein LM, Georas SN, Casolaro V (2001) Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 97:1742鈥?749 CrossRef
86. Perez G, Melo M, Keegan AD, Zamorano J (2002) Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol 168:1428鈥?434
87. Steinke JW, Culp JA, Kropf E, Borish L (2009) Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 124:724鈥?30 CrossRef
88. Choi S, Park HS, Cheon MS, Lee K (2005) Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz) 53:151鈥?58
89. Devouassoux G, Pachot A, Laforest L, Diasparra J, Freymond N, Van Ganse E, Mougin B, Pacheco Y (2008) Galectin-10 mRNA is overexpressed in peripheral blood of aspirin-induced asthma. Allergy 63:125鈥?31
90. Shin S, Park JS, Kim YJ, Oh T, An S, Park CS (2012) Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD. Mol Genet Genomics 287:361鈥?71 CrossRef
91. Sekigawa T, Tajima A, Hasegawa T, Hasegawa Y, Inoue H, Sano Y, Matsune S, Kurono Y, Inoue I (2009) Gene-expression profiles in human nasal polyp tissues and identification of genetic susceptibility in aspirin-intolerant asthma. Clin Exp Allergy 39:972鈥?81 CrossRef
92. Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Schennach H, Fuchs D (2005) Aspirin downregulates homocysteine formation in stimulated human peripheral blood mononuclear cells. Scand J Immunol 62:155鈥?60 CrossRef
93. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261:472鈥?75 CrossRef
94. Porreca E, Reale M, Di FC, Di GM, Barbacane RC, Castellani ML, Baccante G, Conti P, Cuccurullo F (1996) Down-regulation of cyclooxygenase-2 (COX-2) by interleukin-1 receptor antagonist in human monocytes. Immunology 89:424鈥?29 CrossRef
95. Stankovic KM, Goldsztein H, Reh DD, Platt MP, Metson R (2008) Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. Laryngoscope 118:881鈥?89 CrossRef
96. Zander KA, Saavedra MT, West J, Scapa V, Sanders L, Kingdom TT (2009) Protein microarray analysis of nasal polyps from aspirin-sensitive and aspirin-tolerant patients with chronic rhinosinusitis. Am J Rhinol Allergy 23:268鈥?72 CrossRef
97. Cheong HS, Park SM, Kim MO, Park JS, Lee JY, Byun JY, Park BL, Shin HD, Park CS (2011) Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics. Allergy 66:637鈥?44 CrossRef
98. Wenzel SE (2006) Asthma: defining of the persistent adult phenotypes. Lancet 368:804鈥?13 CrossRef
99. Moon HG, Tae YM, Kim YS, Gyu JS, Oh SY, Song GY, Zhu Z, Kim YK (2010) Conversion of Th17-type into Th2-type inflammation by acetyl salicylic acid via the adenosine and uric acid pathway in the lung. Allergy 65:1093鈥?103 - 作者单位：Juan R. Velazquez (1)
Luis M. Teran (1)
1. Departamento de Inmunogen茅tica y Alergia, Instituto Nacional de Enfermedades Respiratorias (INER), Mexico City, Mexico - ISSN：1559-0267
文摘
Aspirin-exacerbated respiratory disease is a tetrad of nasal polyps, chronic hypertrophic eosinophilic sinusitis, asthma, and sensitivity to aspirin. Unawareness of this clinical condition by patients and physicians may have grave consequences because of its association with near-fatal asthma. The pathogenesis of aspirin-intolerant asthma is not related with an immunoglobin E mechanism, but with an abnormal metabolism of the lipoxygenase (LO) and cyclooxygenase (COX) pathways. At present, a diagnosis of aspirin sensitivity can be established only by provocative aspirin challenge, which represents a health risk for the patient. This circumstance has encouraged the search for aspirin intolerance-specific biomarkers. Major attempts have focused on mediators related with inflammation and eicosanoid regulation. The use of modern laboratory techniques including high-throughput methods has facilitated the detection of dozens of biological metabolites associated with aspirin-intolerant asthma disease. Not surprisingly, the majority of these is implicated in the LO and COX pathways. However, substantial amounts of data reveal the participation of many genes deriving from different ontologies. Biomarkers may represent a powerful, noninvasive tool in the diagnosis of aspirin sensitivity; moreover, they could provide a new way to classify asthma phenotypes.